Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients

Ma, Terry King Wing; Chow, Kai Ming; Choy, Agnes Shin Man; Kwan, Bonnie Ching Ha; Szeto, Cheuk Chun; Li, Philip Kam-Tao

doi:10.1093/ckj/sfu098

Cited by 27 publications

(14 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Gram stain of exit-site drainage may help to guide the subsequent antibiotic therapy. Dosing recommendations for frequently used oral antibiotics are shown in Table 4 (86,144,145,165,(182)(183)(184)(185)(186)(187)(188)(189)(190)(191)(192)(193)(194)(195). The presence of granulation tissue over the exit site without other features of infection does not require antibiotic treatment.…”

Section: Empirical Antibiotic Treatmentmentioning

confidence: 99%

ISPD Catheter-Related Infection Recommendations: 2017 Update

et al. 2017

View full text Add to dashboard Cite

Section: Empirical Antibiotic Treatmentmentioning

confidence: 99%

ISPD Catheter-Related Infection Recommendations: 2017 Update

et al. 2017

View full text Add to dashboard Cite

“…Toxicity of these agents in patients with renal failure has been observed. The dose should be reduced based on renal function [44]. …”

Section: Pharmacokinetics and Pharmacodynamics Of Anti-infective Agenmentioning

confidence: 99%

Optimization of anti-infective dosing regimens during online haemodiafiltration

Jager

Zandvliet

Touw

et al. 2017

Clinical Kidney Journal

View full text Add to dashboard Cite

Online haemodiafiltration (HDF) is increasingly used in clinical practice as a routine intermittent dialysis modality. It is well known that renal impairment and renal replacement therapy can substantially affect the pharmacokinetic behaviour of several drugs. However, surprisingly few data are available on the need for specific dose adjustments during HDF. Due to convection, drug clearance may be increased during HDF as compared with standard haemodialysis. This may be of particular interest in patients undergoing anti-infective therapy, since under-dosing may compromise patient outcomes and promote the emergence of bacterial resistance. Drug clearance during HDF is determined by (i) dialysis characteristics, (ii) drug characteristics and (iii) patient characteristics. In this review, we will discuss these different determinants of drug clearance during HDF and advise on how to adjust the dose of antibacterial, antimycotic and antiviral agents in patients undergoing HDF. In addition, the possible added value of therapeutic drug monitoring is discussed. The review provides guidance for optimization of anti-infective dosing regimens in HDF patients.

show abstract

“…Given the alarming healthcare conditions related to microbial infection, tremendous interest has been straightened towards the development of novel antimicrobials. Drug resistance phenomena related to pathogenic microorganisms [ 1 , 2 , 3 ] and the lack of specificity and side effects related to conventional pharmaceuticals [ 4 , 5 , 6 ] utilized in high amounts to treat severe infection represent one of the top concerns in scientific world. The experimental development and implementation of novel formulations with specific and selective antimicrobial activity is gathering interest worldwide from both healthcare practitioners and scientists.…”

Section: Introductionmentioning

confidence: 99%

Antibiofilm Coatings Based on PLGA and Nanostructured Cefepime-Functionalized Magnetite

et al. 2018

View full text Add to dashboard Cite

The aim of our study was to obtain and evaluate the properties of polymeric coatings based on poly(lactic-co-glycolic) acid (PLGA) embedded with magnetite nanoparticles functionalized with commercial antimicrobial drugs. In this respect, we firstly synthesized the iron oxide particles functionalized (@) with the antibiotic Cefepime (Fe3O4@CEF). In terms of composition and microstructure, the as-obtained powdery sample was investigated by means of grazing incidence X-ray diffraction (GIXRD), thermogravimetric analysis (TGA), scanning and transmission electron microscopy (SEM and TEM, respectively). Crystalline and nanosized particles (~5 nm mean particle size) with spherical morphology, consisting in magnetite core and coated with a uniform and reduced amount of antibiotic shell, were thus obtained. In vivo biodistribution studies revealed the obtained nanoparticles have a very low affinity for innate immune-related vital organs. Composite uniform and thin coatings based on poly(lactide-co-glycolide) (PLGA) and antibiotic-functionalized magnetite nanoparticles (PLGA/Fe3O4@CEF) were subsequently obtained by using the matrix assisted pulsed laser evaporation (MAPLE) technique. Relevant compositional and structural features regarding the composite coatings were obtained by performing infrared microscopy (IRM) and SEM investigations. The efficiency of the biocompatible composite coatings against biofilm development was assessed for both Gram-negative and Gram-positive pathogens. The PLGA/Fe3O4@CEF materials proved significant and sustained anti-biofilm activity against staphylococcal and Escherichia coli colonisation.

show abstract

Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients

Cited by 27 publications

References 57 publications

ISPD Catheter-Related Infection Recommendations: 2017 Update

ISPD Catheter-Related Infection Recommendations: 2017 Update

Optimization of anti-infective dosing regimens during online haemodiafiltration

Antibiofilm Coatings Based on PLGA and Nanostructured Cefepime-Functionalized Magnetite

Contact Info

Product

Resources

About